Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases. “The current ...

Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio's ...

Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company's strategic decision to focus on cardiovascular diseases.